Price Discount Paves The Way For NICE To Clear GSK’s Revolade

U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.

Discounted pricing as part of a patient access scheme has reversed a three-year-old rejection of GlaxoSmithKline PLC's oral platelet booster, Revolade (eltrombopag) for reimbursement by the U.K.'s National Health Service.

The National Institute for Health and Care Excellence (NICE) issued draft final guidance June 12 saying Revolade, marketed as Promacta...

More from United Kingdom

More from Europe